Centre De Lutte Contre Le Cancer Eugene Marquis
Rennes, France
Not recruiting
Study of BT8009 and Pembrolizumab for Patients with Advanced Cancers Expressing Nectin-4
Fast replyRegistered drug
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying advanced cancers that express a protein called Nectin-4. The study is investigating a new treatment called BT8009, which is given as a solution through an intravenous infusion. In some parts of the study, BT8009 is used alone, while in others, it is combined with another medication called Pembrolizumab. The purpose of the study is to assess the safety and initial effectiveness of BT8009 in patients with these types of cancers.
Participants in the study will receive the treatment over a period of time, and researchers will monitor them to see how their bodies respond. The study will look at how well the treatment is tolerated and how it affects the cancer. Some patients will receive BT8009 by itself, while others will receive it in combination with Pembrolizumab. The study will also include patients with different levels of kidney function to understand how the treatment works in these conditions.
The study aims to find the most suitable dose of BT8009 and to gather information on how the drug moves through the body. Researchers will also evaluate the overall response of the cancer to the treatment. This information will help determine if BT8009 could be a potential treatment option for patients with advanced cancers that express Nectin-4.
The research process
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
17 criteria
- The patient must provide a signed and dated written consent form before any study-related procedures, tests, or analyses are done.
- The patient must be at least 18 years old at the time of signing the consent form.
- The patient should have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1, which means they are fully active or have some restrictions but can still do light work. Patients with certain types of cancer may have a score of 2, which means they are capable of all self-care but unable to carry out any work activities.
- The patient must have a measurable disease according to specific criteria used to evaluate tumors. This means the disease can be measured and tracked over time.
- The patient must have acceptable organ function, which includes:
- Good kidney function, shown by a creatinine clearance of at least 50 mL/min.
- Normal levels of bilirubin, a substance made by the liver, unless they have a specific condition called Gilbert syndrome.
- Serum albumin, a protein in the blood, should be at least 2.5 g/dL.
- Normal levels of liver enzymes, unless there are liver metastases, which are cancer spread to the liver.
- A normal blood clotting ability, unless the patient is on stable anticoagulant therapy.
- The patient must have acceptable blood function, which means:
- Hemoglobin levels of at least 9 g/dL, which is important for carrying oxygen in the blood.
- An absolute neutrophil count (ANC) of at least 1500 cells/mm3, which is important for fighting infections.
- A platelet count of at least 75,000 cells/mm3, which is important for blood clotting.
- Women who can become pregnant must have a negative pregnancy test before starting the treatment.
- The patient must have available tumor samples from previous tests or be willing to provide a new tumor biopsy during the screening process.
- The patient must have a life expectancy of at least 12 weeks after starting the treatment, as judged by the doctor.
- The patient must be willing and able to follow the study's rules, including attending scheduled visits, following the treatment plan, and undergoing tests and procedures.
- Additional specific criteria may apply depending on the group or part of the study the patient is in.
Who cannot join the trial?
7 criteria
- Patients who have a different type of cancer that does not express Nectin-4. Nectin-4 is a protein that can be found on the surface of some cancer cells.
- Patients who have not been exposed to EV (enfortumab vedotin) if they are in certain groups of the study. EV is a type of cancer treatment.
- Patients who are eligible for cisplatin treatment if they are in certain groups of the study. Cisplatin is a common chemotherapy drug.
- Patients who do not have moderate to severe renal insufficiency if they are in the specific group studying this condition. Renal insufficiency means the kidneys are not working as well as they should.
- Patients who do not have urothelial carcinoma if they are in the specific group studying this type of cancer. Urothelial carcinoma is a cancer that occurs in the urinary system.
- Patients who do not have ovarian cancer, triple-negative breast cancer (TNBC), or non-small cell lung cancer (NSCLC) if they are in the specific groups studying these cancers.
- Patients who are not able to follow the study's treatment schedule, which includes specific days for receiving the medication.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified Verified Centre Leon Berard
Lyon, FranceResponsive Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
Madrid, Spain
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
BT8009 (Zelenectide Pevedotin)
is an investigational medication being studied for its safety and effectiveness in treating advanced cancers that express a protein called Nectin-4. It is being tested both as a standalone treatment and in combination with another medication. The study aims to understand how well this medication works in shrinking tumors and how the body processes it.
Pembrolizumab
is a medication used in combination with BT8009 in this study. It is an immunotherapy drug that helps the immune system recognize and attack cancer cells. The combination is being tested to see if it improves treatment outcomes for patients with certain types of cancer.
What is already known about the treatment
Zelenectide Pevedotin – This medication is administered intravenously and is currently being studied in clinical trials for its safety and effectiveness in treating advanced solid tumors that express Nectin-4. It is primarily used for patients with urothelial carcinoma and other solid tumors like ovarian, triple-negative breast cancer, and non-small cell lung cancer. Zelenectide Pevedotin works by targeting and binding to Nectin-4 on cancer cells, delivering a toxic agent that disrupts cell division, leading to cancer cell death. It is classified as an antibody-drug conjugate, combining a monoclonal antibody with a cytotoxic drug to specifically target cancer cells while minimizing damage to normal cells.
Investigated diseases
Advanced Solid Tumor Malignancies
These are cancers that have spread beyond their original site and are characterized by uncontrolled cell growth. They can occur in various organs and tissues, leading to a range of symptoms depending on the location and size of the tumor. As the disease progresses, it may invade nearby tissues and organs, potentially causing pain and dysfunction. The tumors can also metastasize, meaning they spread to distant parts of the body, complicating treatment and management. The progression of these malignancies can vary widely, influenced by factors such as the type of cancer and the patient's overall health.
Urothelial Carcinoma
This is a type of cancer that typically begins in the cells lining the bladder, but it can also occur in other parts of the urinary tract. It is characterized by the abnormal growth of urothelial cells, which can form tumors. As the disease advances, it may invade deeper layers of the bladder wall and spread to nearby lymph nodes and other organs. Symptoms often include blood in the urine, frequent urination, and pain during urination. The progression of urothelial carcinoma can lead to more severe symptoms and complications if it spreads beyond the urinary tract.
Ovarian Cancer
This cancer originates in the ovaries and is known for its subtle symptoms in the early stages, such as bloating, pelvic pain, and changes in bowel habits. As it progresses, the cancer can spread to the pelvis and abdomen, leading to more pronounced symptoms and complications. The disease often goes undetected until it has advanced, making it more challenging to manage. The progression involves the growth and spread of cancerous cells, which can affect the function of nearby organs.
Triple-Negative Breast Cancer (TNBC)
This is a subtype of breast cancer that lacks the three most common types of receptors known to fuel most breast cancer growth. It is characterized by its aggressive nature and tendency to spread more quickly than other types of breast cancer. TNBC can be more challenging to treat due to the absence of targeted receptors. As the disease progresses, it may spread to other parts of the body, leading to more complex symptoms and treatment challenges. The progression can vary, but it often requires a comprehensive approach to management.
Non-Small Cell Lung Cancer (NSCLC)
This is the most common type of lung cancer, accounting for a majority of cases. It begins in the tissues of the lungs and can grow and spread to other parts of the body. Symptoms may include a persistent cough, chest pain, and shortness of breath. As NSCLC progresses, it can invade nearby tissues and organs, leading to more severe symptoms and complications. The disease's progression is influenced by factors such as the stage at diagnosis and the patient's overall health.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-509781-37-00Protocol codeBT8009-100Estimated enrolment430 patientsSponsorBicycletx Limited
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?